Human EDIL3 Antibody

Catalog #: AF6046 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
AF6046
AF6046-SP

Detection of Human EDIL3 by Western Blot.

2 Images

All EDIL3 Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human EDIL3 Antibody Summary

Species Reactivity

Human

Specificity

Detects human EDIL3 in direct ELISAs and Western blots.

Source

Polyclonal Sheep IgG

Purification

Antigen Affinity-purified

Immunogen

Chinese hamster ovary cell line CHO-derived recombinant human EDIL3
Val17-Glu480
Accession # O43854

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

See below

Immunocytochemistry

5-15 µg/mL

See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Western Blot

View Larger

Detection of Human EDIL3 by Western Blot. Western blot shows lysates of SH-SY5Y human neuroblastoma cell line, MDA-MB-231 human breast cancer cell line, HFL1 human fetal lung fibroblast cell line, and MRC-5 human embryonic lung fibroblast cell line. PVDF Membrane was probed with 1 µg/mL of Sheep Anti-Human EDIL3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6046) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for EDIL3 at approximately 52-54 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Immunocytochemistry

View Larger

EDIL3 in MDA‑MB‑231 Human Cell Line. EDIL3 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using Sheep Anti-Human EDIL3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6046) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Sterile PBS to a final concentration of 0.2 mg/mL.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: EDIL3

EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3; also Del-1 and integrin-binding DEL1) is a 52 kDa extracellular matrix protein that is expressed by endothelial tissues during embryonic vascular development (1). Human EDIL3 is synthesized as a precursor with a 16 amino acid (aa) signal sequence and a 464 aa mature chain. The mature chain is composed of three epidermal growth factor (EGF) repeats and two discoidin-I-like domains (1). The second EGF repeat contains an RGD motif (1). Splicing variants produce two isoforms for human EDIL3. Isoform 2 has an A->G substitution at aa 66 and a deletion of aa 67‑76 found in isoform 1. Mature human EDIL3 shares 96% aa sequence identity with mature mouse EDIL3. The RGD motif of EDIL3 binds alpha v beta 5 integrin, which, in turn, leads to increased angiogenic transcription factor HoxD3 expression (2). HoxD3activates alpha v beta 3 and uPA, resulting in the transformation of resting endothelial cells to an angiogenic state (2‑4).

EDIL3 becomes quiescent at the time of birth, and is no longer expressed in normal adult tissues. It has been found, however, re-expressed in a number of human tumors as well as in ischemic muscles and ischemic brain tissue, which may play an important role in adult angiogenesis (2, 5‑6). EDIL3 promotes adherence and migration of endothelial cells, and acts as an endothelial cell survival agent through upregulation of Bcl-2 expression (7). Exogenous application of EDIL3 has been demonstrated to augment angiogenesis and improve blood flow and tissue function in murine models of hind-limb ischemia (6, 8), cardiac ischemia (9) and cerebral ischemia (2). EDIL3 has also been shown to be an endogenous inhibitor of inflammatory cell recruitment by interfering with the integrin LFA-1-dependent leukocyte‑endothelial adhesion (10).

References

Hidai, C. et al. (1998) Genes Dev. 12:21.
Fan, Y. et al. (2008) Brain Res. 1219:1.
Penta, K. et al. (1999) J. Biol. Chem. 274:11101.
Rezaee, M. et al. (2002) Am. J. Physiol. Heart Circ. Physiol. 282:H1924.
Aoka, Y. et al. (2002) Microvasc. Res. 64:148.
Ho, H.K. et al. (2004) Circulation 109:1314.
Pollman, M.J. et al. (1999) J. Cell Physiol. 178:359.
Zhong, J. et al. (2003) J. Clin. Invest. 112:30.
Kown, M.H. et al. (2003) Ann. Thorac. Surg. 76:1246.
Choi, E.Y. et al. (2008) Science 322:1101.

Entrez Gene IDs

10085 (Human); 13612 (Mouse)

Alternate Names

DEL1; DEL1developmental endothelial locus-1; Developmentally-regulated endothelial cell locus 1 protein; EDIL3; EGF-like repeat and discoidin I-like domain-containing protein 3; EGF-like repeats and discoidin I-like domains 3; Integrin-binding protein DEL1; MGC26287